324 related articles for article (PubMed ID: 11929983)
21. Preparation, characterization and refolding in vitro of a recombinant human cyclophilin A mutant: effect of a single Pro/Ser substitution on cyclophilin A structure and properties.
Xu LR; Yan X; Luo M; Guan YX; Yao SJ
Biotechnol Prog; 2008; 24(2):302-10. PubMed ID: 18333624
[TBL] [Abstract][Full Text] [Related]
22. HIV protease substrate conformation: modulation by cyclophilin A.
McCornack MA; Kakalis LT; Caserta C; Handschumacher RE; Armitage IM
FEBS Lett; 1997 Sep; 414(1):84-8. PubMed ID: 9305737
[TBL] [Abstract][Full Text] [Related]
23. Acetylation regulates cyclophilin A catalysis, immunosuppression and HIV isomerization.
Lammers M; Neumann H; Chin JW; James LC
Nat Chem Biol; 2010 May; 6(5):331-7. PubMed ID: 20364129
[TBL] [Abstract][Full Text] [Related]
24. Structural insights into the stabilization of the human immunodeficiency virus type 1 capsid protein by the cyclophilin-binding domain and implications on the virus cycle.
Cortines JR; Lima LM; Mohana-Borges R; Millen Tde A; Gaspar LP; Lanman JK; Prevelige PE; Silva JL
Biochim Biophys Acta; 2015 May; 1854(5):341-8. PubMed ID: 25526889
[TBL] [Abstract][Full Text] [Related]
25. Cyclophilin A binds to linear peptide motifs containing a consensus that is present in many human proteins.
Piotukh K; Gu W; Kofler M; Labudde D; Helms V; Freund C
J Biol Chem; 2005 Jun; 280(25):23668-74. PubMed ID: 15845542
[TBL] [Abstract][Full Text] [Related]
26. Novel inhibitor binding site discovery on HIV-1 capsid N-terminal domain by NMR and X-ray crystallography.
Goudreau N; Lemke CT; Faucher AM; Grand-Maître C; Goulet S; Lacoste JE; Rancourt J; Malenfant E; Mercier JF; Titolo S; Mason SW
ACS Chem Biol; 2013 May; 8(5):1074-82. PubMed ID: 23496828
[TBL] [Abstract][Full Text] [Related]
27. Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop.
Gatanaga H; Das D; Suzuki Y; Yeh DD; Hussain KA; Ghosh AK; Mitsuya H
J Biol Chem; 2006 Jan; 281(2):1241-50. PubMed ID: 16275650
[TBL] [Abstract][Full Text] [Related]
28. Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A.
Brazin KN; Mallis RJ; Fulton DB; Andreotti AH
Proc Natl Acad Sci U S A; 2002 Feb; 99(4):1899-904. PubMed ID: 11830645
[TBL] [Abstract][Full Text] [Related]
29. Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression.
Zander K; Sherman MP; Tessmer U; Bruns K; Wray V; Prechtel AT; Schubert E; Henklein P; Luban J; Neidleman J; Greene WC; Schubert U
J Biol Chem; 2003 Oct; 278(44):43202-13. PubMed ID: 12881522
[TBL] [Abstract][Full Text] [Related]
30. Cyclophilin A inhibition: targeting transition-state-bound enzyme conformations for structure-based drug design.
Nagaraju M; McGowan LC; Hamelberg D
J Chem Inf Model; 2013 Feb; 53(2):403-10. PubMed ID: 23312027
[TBL] [Abstract][Full Text] [Related]
31. The cysteine residues of HIV-1 capsid regulate oligomerization and cyclophilin A-induced changes.
Bon Homme M; Carter C; Scarlata S
Biophys J; 2005 Mar; 88(3):2078-88. PubMed ID: 15626706
[TBL] [Abstract][Full Text] [Related]
32. Crystal structures of cyclophilin and its partners.
Ke H; Huai Q
Front Biosci; 2004 Sep; 9():2285-96. PubMed ID: 15353287
[TBL] [Abstract][Full Text] [Related]
33. Two conformational states of Turkey ovomucoid third domain at low pH: three-dimensional structures, internal dynamics, and interconversion kinetics and thermodynamics.
Song J; Laskowski M; Qasim MA; Markley JL
Biochemistry; 2003 Jun; 42(21):6380-91. PubMed ID: 12767219
[TBL] [Abstract][Full Text] [Related]
34. Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid.
Li J; Tan Z; Tang S; Hewlett I; Pang R; He M; He S; Tian B; Chen K; Yang M
Bioorg Med Chem; 2009 Apr; 17(8):3177-88. PubMed ID: 19328002
[TBL] [Abstract][Full Text] [Related]
35. What is so special about Arg 55 in the catalysis of cyclophilin A? insights from hybrid QM/MM simulations.
Li G; Cui Q
J Am Chem Soc; 2003 Dec; 125(49):15028-38. PubMed ID: 14653737
[TBL] [Abstract][Full Text] [Related]
36. Maturation-induced conformational changes of HIV-1 capsid protein and identification of two high affinity sites for cyclophilins in the C-terminal domain.
Endrich MM; Gehrig P; Gehring H
J Biol Chem; 1999 Feb; 274(9):5326-32. PubMed ID: 10026140
[TBL] [Abstract][Full Text] [Related]
37. A molecular dynamics study of Cyclophilin A free and in complex with the Ala-Pro dipeptide.
Mark P; Nilsson L
Eur Biophys J; 2007 Mar; 36(3):213-24. PubMed ID: 17225137
[TBL] [Abstract][Full Text] [Related]
38. The host-pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains.
Solbak SM; Wray V; Horvli O; Raae AJ; Flydal MI; Henklein P; Henklein P; Nimtz M; Schubert U; Fossen T
BMC Struct Biol; 2011 Dec; 11():49. PubMed ID: 22185200
[TBL] [Abstract][Full Text] [Related]
39. In vitro assembly properties of wild-type and cyclophilin-binding defective human immunodeficiency virus capsid proteins in the presence and absence of cyclophilin A.
Grättinger M; Hohenberg H; Thomas D; Wilk T; Müller B; Kräusslich HG
Virology; 1999 Apr; 257(1):247-60. PubMed ID: 10208938
[TBL] [Abstract][Full Text] [Related]
40. Design of a Gag pentapeptide analogue that binds human cyclophilin A more efficiently than the entire capsid protein: new insights for the development of novel anti-HIV-1 drugs.
Li Q; Moutiez M; Charbonnier JB; Vaudry K; Ménez A; Quéméneur E; Dugave C
J Med Chem; 2000 May; 43(9):1770-9. PubMed ID: 10794694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
